AVLSA
Atlas Venture Life Science Advisors’s Replimune Group REPL Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-2,098,300
| Closed | -$18.9M | – | 15 |
|
|
2024
Q2 | $18.9M | Hold |
2,098,300
| – | – | 1.99% | 10 |
|
|
2024
Q1 | $17.1M | Hold |
2,098,300
| – | – | 1.58% | 11 |
|
|
2023
Q4 | $17.7M | Hold |
2,098,300
| – | – | 2.11% | 9 |
|
|
2023
Q3 | $35.9M | Hold |
2,098,300
| – | – | 5.56% | 6 |
|
|
2023
Q2 | $48.7M | Hold |
2,098,300
| – | – | 6.06% | 7 |
|
|
2023
Q1 | $37.1M | Hold |
2,098,300
| – | – | 5.02% | 8 |
|
|
2022
Q4 | $57.1M | Sell |
2,098,300
-1,010,000
| -32% | -$27.5M | 6.87% | 7 |
|
|
2022
Q3 | $53.7M | Sell |
3,108,300
-101,327
| -3% | -$1.75M | 5.92% | 5 |
|
|
2022
Q2 | $56.1M | Hold |
3,209,627
| – | – | 9.38% | 4 |
|
|
2022
Q1 | $54.5M | Hold |
3,209,627
| – | – | 6.89% | 6 |
|
|
2021
Q4 | $87M | Buy |
+3,209,627
| New | +$87M | 7.99% | 4 |
|